Physician profile
Chad Walter Mayer
NPI 1467423855
$25,180.84
in general payments reported to CMS, 2019-2025
25 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $83.87 · 2021: $62.86 · 2022: $295 · 2023: $1,000 · 2024: $1,811 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,543 · Travel and Lodging: $2,631 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,800.00 |
| Food and Beverage | $6,543.01 |
| Travel and Lodging | $2,630.83 |
| Education | $178.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $18,327.93 | 2025 | Neffy |
| Genzyme Corporation | $1,280.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $971.96 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $918.75 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $758.08 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $651.00 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $315.27 | 2024-2025 | Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $293.41 | 2019-2025 | |
| Pfizer INC. | $281.82 | 2019-2025 | |
| Kaleo, INC. | $258.78 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $187.04 | 2019-2025 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Blueprint Medicines Corporation | $164.93 | 2023-2025 | Ayvakit |
| Amgen INC. | $153.49 | 2023-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $131.91 | 2024-2025 | Orladeyo |
| Genentech USA, INC. | $117.51 | 2019-2024 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $108.74 | 2024-2025 | Cutaquig, Panzyga |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Tersera Therapeutics LLC | $49.61 | 2021-2024 | Quzyttir |
| Hospira, INC. | $31.61 | 2024-2025 | |
| Incyte Corporation | $24.85 | 2025 | Opzelura |
| Lilly USA, LLC | $24.28 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $19.39 | 2025 | Nemluvio |
| Phadia US INC. | $19.07 | 2025 | Immunocap |
| Shire North American Group INC | $18.59 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.67 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.